Antimicrobial resistance (AMR) is a global health challenge with an estimated 67% increase in global deaths attributable to AMR by 2050. The European Partnership One Health AMR (EUP OHAMR) is aiming to reduce the burden of AMR with an integrated One Health (OH) approach, recognising that human, animal and plant health are interdependent and interlinked with the environment. The partnership will boost AMR research and innovation (R&I) addressing the current knowledge gaps with the aim to improve surveillance of resistant pathogens and provide better diagnostics and more effective treatments of drug-resistant infections. It will support implementation research on prevention measures reducing the use of antimicrobials and spread of AMR and launch an ambitious work programme of joint activities to coordinate R&I investments, facilitate the use and re-use of R&I data, strengthen AMR R&I capacities and facilitate both knowledge translation and uptake of research results and innovations by industry, society, and policy makers. The EUP OHAMR builds on the long-standing collaboration of the partners from the Joint Programme Initiative on AMR (JPIAMR) but with a bigger ambition and a broader scope. The partnership consists of 53 partners from 30 countries from the European Union (EU) and beyond. With active engagement of key stakeholders across the AMR landscape, the partnership will strengthen European and global synergies through alignment of research priorities, policies, and investments. Furthermore, EUP OHAMR will support multisectoral and multidisciplinary collaborations to break the existing silos in AMR research. It will result in increased knowledge and solutions and provide an evidence base for uptake into policy and practice to prevent and tackle AMR. Thus, the EUP OHAMR will deliver towards to the priorities set in the European One Health Action plan against AMR, thereby strengthening the European Research and Innovation Area ecosystem and contribute to making the EU a best-practice region on AMR.

Excellent EU programs push health R&I but are not sufficient. Synergy with strategic initiatives in MS and a new model for impactful collaborations are needed to address the challenges for health. ERA4Health brings the opportunity to increase EU transnational collaborative research funding by creating a funding body for joint programming in priority areas addressing EU Public Health Needs, with total duration of 7 years. ERA4Health focuses on tackling diseases and reducing disease burden and the following challenges: 1) the increasing demand for a better quality of life and a better care of patients, 2) the need to transform public health care systems in more effective, efficient, equitable, accessible, and resilient ones and 3) the need to strengthen disease prevention and health promotion. In this view, ERA4Health objectives are: .SO1- Support relevant medical research including clinical fields and intervention areas (prevention, diagnosis, treatment) .SO2- Improve the utilisation of existing health technologies in clinical practice .SO3- Build capacity, in particular in conducting Investigator Initiated Clinical Studies at EU scale .SO4- Implement and advance the practice of RRI across the breadth of the programme ERA4Heatlth will be implemented in 2 phases: . Phase 1 (2 years) will implement joint calls focused on nutrition and lifestyle-related diseases, cardiovascular diseases and nanomedicine (4 in two years). In parallel, it will establish a supporting framework to overcome the challenges in launching international IICSs joint calls. . Phase 2, if the EC approves it: additional multinational calls for IICSs and joint calls for other priority areas will be launched in accordance with the decision of the Health Programme Committee taken at the end of previous Phase 34 partners (20 from EU, 3 Third Countries associated to HE and 2 non-associated, non EU), will commit 90,510,000€, during the 3 first years, as financial support to third parties.

The European Rare Diseases Research Alliance (ERDERA) aims to improve the health and well-being of the 30 million people living with a rare disease in Europe, by making Europe a world leader in Rare Disease (RD) research and innovation, to support concrete health benefits to rare disease patients, through better prevention, diagnosis and treatment. This Partnership will deliver a RD ecosystem that builds on the successes of previous programmes by supporting robust patient need-led research, developing new diagnostic methods and pathways, spearheading the digital transformational change connecting the dots between care, patient data and research, while ensuring strong alignment of strategies in RD research across countries and regions. Structuring goal-oriented public-private collaborations targeted at interventions all along the R&D value chain will ensure that the journey from knowledge to patient impact is expedited, thereby optimising EU innovation potential in RD. To support its ambition and missions ERDERA has been designed as a comprehensive and integrated ecosystem of which structure can be compared to an institute encompassing three main parts: (i) funding, (ii) internal (in house) Clinical Research Network that implements research activities targeting clinical trial readiness of RDs and accelerating diagnosis and translation of research discovery into improved patient care, and (iii) related supporting services (Data, Expertise, Education and Training) as well as an acceleration hub that serve external and internal RD community, all supported by all-embracing coordination and strategy and foundational (inter)national alignment.

X-eHealth’s project stands herein for a project of strategic relevance for tomorrow’s European eHealth Union. Assembling at the time of this proposal submission a shared commitment of 47 health actors, the underlying idea of this project is to develop the basis for a workable, interoperable, secure and cross border Electronic Health Record exchange Format in order to lay the foundation for the advance of eHealth sector while using the 3 pillars put forward by the EC as reference. Aimed at promoting a faster and sustainable EU digital transformation, this Cooperative and Support Action is made up of 8 Work Package in which 4 exclusively focus on technical-functional activities (WP4 to WP7). From Generic Aspects to System Architecture and Integration, passing by Functional and Technical Specifications, X-eHealth objective is to move towards a uniform interoperable data-sharing format framework. In addition, to enhance EU’s public health state of play, WP1 and WP8 are responsible for implementation studies, practicality and continuity of eHealth interoperability development. On this basis and building upon the already in place Patient Summary, X-eHealth purpose is to develop the foundations for a common framework for medical imaging, discharge letters, laboratory results and rare diseases to flow both alongside citizens care pathway and across health entities between EU Member States and Neighbour Countries. Focus on cross-border services, this consortium aims to advance an interoperable Common European Health Data Space for citizens and health providers engagement in accordance with privacy and cybersecurity regulations. To achieve this end, X-eHealth gathers 36 consortium partners plus 5 collaborative partners and 6 eHealth skilled experts, eager to develop the abovementioned 4 domains, and distinguished by policy and political actors mixed with national competent authorities to indeed concretely plan, implement and maintain national eHealth infrastructures.